REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION

复制病毒载体作为新生儿疫苗以预防 SIV 口腔传播

• 批准号: 7349694
• 负责人: Marta L Marthas
• 金额: $ 15.67万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349694
• 关键词: REPLICATING; VIRAL; VECTOR; NEONATAL; VACCINE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To provide protection against repeated exposure to HIV in breastmilk, a neonatal HIV vaccine should elicit anti-HIV immunity at the initial site of virus exposure the oral cavity as well as throughout the infants body. Attenuated viruses that stably express HIV proteins and replicate in the oral cavity and the gastrointestinal tract could be efficient HIV vaccines.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。目的：为了防止母乳中反复暴露于HIV，新生儿HIV疫苗应在病毒暴露的初始部位引起抗HIV免疫，口腔腔以及整个婴儿体内。稳定表达HIV蛋白并在口腔中复制的减毒病毒和胃肠道可能是有效的HIV疫苗。